2 weeks Ago By Defense World Staff
JPMorgan Chase & Co. grew its position in shares of Tempus AI, Inc. (NASDAQ:TEM – Free Report) by 86,947.
2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,653,896 shares of the company’s stock after acquiring an additional 1,651,996 shares during the period. JPMorgan Chase & Co.
owned about 1.05% of Tempus AI worth $55,836,000 as of its most recent SEC filing. Other institutional investors also recently modified their holdings of the company.
Farther Finance Advisors LLC purchased a new position in Tempus AI during the 4th quarter valued at about $34,000. Prestige Wealth Management Group LLC grew its position in shares of Tempus AI by 910.4% in the 4th quarter.
Prestige Wealth Management Group LLC now owns 1,071 shares of the company’s stock worth $36,000 after buying an additional 965 shares during the last quarter. First Horizon Advisors Inc. increased its stake in shares of Tempus AI by 207.
9% during the fourth quarter. First Horizon Advisors Inc. now owns 1,641 shares of the company’s stock valued at $55,000 after buying an additional 1,108 shares during the period.
FNY Investment Advisers LLC bought a new position in shares of Tempus AI during the fourth quarter valued at approximately $67,000. Finally, IFP Advisors Inc purchased a new stake in Tempus AI in the fourth quarter worth $76,000. 24.
22% of the stock is currently owned by hedge funds and other institutional investors. Tempus AI Price PerformanceNASDAQ TEM opened at $42.58 on Friday.
Tempus AI, Inc. has a 12 month low of $22.89 and a 12 month high of $91.
45. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.
69 and a quick ratio of 2.55. The stock’s fifty day moving average price is $58.
27 and its 200-day moving average price is $51.45. Wall Street Analyst Weigh InA number of brokerages have issued reports on TEM.
TD Cowen reissued a “buy” rating and set a $74.00 price objective (up from $58.00) on shares of Tempus AI in a research report on Wednesday, February 5th.
JPMorgan Chase & Co. downgraded shares of Tempus AI from an “overweight” rating to a “neutral” rating and increased their price target for the stock from $50.00 to $55.
00 in a research note on Tuesday, February 25th. Wolfe Research cut Tempus AI from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 26th. Needham & Company LLC increased their target price on Tempus AI from $56.
00 to $70.00 and gave the stock a “buy” rating in a research report on Tuesday, February 25th. Finally, Guggenheim restated a “buy” rating on shares of Tempus AI in a research report on Tuesday, February 25th.
Six investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $61.
18.View Our Latest Stock Report on TEMInsider Buying and SellingIn other news, Director Wayne A.I.
Frederick sold 3,000 shares of the business’s stock in a transaction on Monday, March 31st. The stock was sold at an average price of $45.54, for a total value of $136,620.
00. Following the completion of the transaction, the director now owns 26,514 shares in the company, valued at $1,207,447.56.
The trade was a 10.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Also, COO Ryan Fukushima sold 20,000 shares of the stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $39.61, for a total value of $792,200.
00. Following the sale, the chief operating officer now directly owns 982,442 shares in the company, valued at $38,914,527.62.
This trade represents a 2.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here.
Insiders have sold a total of 5,601,969 shares of company stock worth $317,330,782 in the last quarter. Tempus AI Company Profile (Free Report)Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.
Recommended StoriesFive stocks we like better than Tempus AIWhat is a Secondary Public Offering? What Investors Need to KnowConagra Stock Could Thrive as Tariffs Hit Other SectorsInsider Trading – What You Need to KnowGrocery Costs and Tariffs Now Top of Mind in Everyday Conversations, New Survey FindsWhat Does a Stock Split Mean? Spotify Stock Eyes Double-Digit Upside—Is Now the Time to Buy?Want to see what other hedge funds are holding TEM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tempus AI, Inc. (NASDAQ:TEM – Free Report).
.
